OrthoPediatrics Supports PNOC's $50 Million Initiative Against Pediatric Brain Cancer
- The PNOC Foundation launched the $50 million Lose No Child campaign to combat pediatric brain cancer.
- Over the past decade, PNOC has raised $25 million, facilitating 30 clinical trials for rare brain cancers.
- The campaign focuses on developing clinical trials and enhancing access to innovative therapies for children in need.
Accelerating Progress in Pediatric Brain Cancer Treatment: The PNOC Foundation's Bold Initiative
The PNOC Foundation has unveiled the Lose No Child campaign, a significant $50 million initiative designed to combat pediatric brain cancer. This aggressive campaign emerges in response to the alarming fact that brain cancer is the leading cause of cancer-related deaths among children and young adults. By aiming to achieve advancements in pediatric oncology that typically take a decade within just five years, the foundation seeks to revolutionize the landscape of treatments available for young patients. With a commitment to expedite the development and implementation of safer and more effective therapies, the Lose No Child campaign is poised to make a monumental impact on the lives of children battling this devastating disease.
Over the last decade, the PNOC Foundation has made noteworthy progress in pediatric brain cancer research, having raised over $25 million. This funding has facilitated the launch of more than 30 clinical trials, involving over 1,000 children diagnosed with rare brain cancers. Notably, these efforts have led to two groundbreaking FDA approvals for innovative treatments, highlighting the foundation's role as a catalyst for change in this critical field. As the foundation continues to harness the collective expertise of over 300 researchers from 43 institutions globally, it remains dedicated to addressing the multifaceted challenges presented by various types of pediatric brain tumors.
Dr. Michael Prados, Co-Founder of PNOC and Professor Emeritus at UCSF, underscores the importance of collaboration in driving swift advancements in treatment options. The Lose No Child campaign allocates its funding to three primary areas: 50% is designated for the development and implementation of clinical trials, which includes the integration of artificial intelligence in study designs, patient recruitment, and regulatory compliance. An additional 30% of funds will focus on enhancing access to innovative therapies for children in need. As the campaign continues its fundraising efforts through 2028, it builds on the foundation's momentum to redefine the pace of progress in treating the deadliest childhood cancers.
In parallel to these advancements, the campaign has already raised $12 million during its silent phase, demonstrating strong initial support from donors and stakeholders. This financial backing is instrumental in ensuring that the PNOC Foundation can maintain its trajectory of innovation and progress in pediatric oncology research. The foundation's comprehensive approach not only aims to enhance treatment options but also emphasizes the critical need for collaboration among researchers, clinicians, and industry leaders to transform the future of pediatric brain cancer care.